<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00982189</url>
  </required_header>
  <id_info>
    <org_study_id>PCC-003</org_study_id>
    <nct_id>NCT00982189</nct_id>
  </id_info>
  <brief_title>Cardiovascular Prevention for Persons With HIV</brief_title>
  <official_title>Cardiovascular Disease Risk Reduction for Persons With HIV Infection: a Polypill Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minneapolis Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Minneapolis Medical Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is funded by the American Heart Association. The goal of this research is to
      prevent early cardiovascular damage before symptoms develop for persons with HIV infection.
      Evidence suggests that taking low doses of blood pressure and cholesterol medication reduces
      risk for heart disease in persons who are at increased risk (such as the case with HIV
      infection).

      Participants who are taking HIV treatment with an 'undetectable' viral load, and who do NOT
      need treatment for high blood pressure or cholesterol may be eligible to enroll. Participants
      will take a low dose cholesterol medication (or placebo) and a low dose of a blood pressure
      medication (or a placebo), and will be seen at 3 study visits over 4 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Stated (by Self-report) That They Had Side Effects</measure>
    <time_frame>4 months</time_frame>
    <description>Participants were asked at each visit if they had any side effects to study medication. They provided a yes or no answer, and if yes they specified what the side effect was.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Took &gt;90% of Their Doses (by Pill Count)</measure>
    <time_frame>4 months</time_frame>
    <description>The number of pills missing from study medication bottles was counted by study nurses at the completion of the study. The proportion of pills taken divided by the number of days the participant was enrolled in the study was calculated, and multiplied by 100, to generate the '% of doses taken'</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Month 4 in the Framingham Risk Score (FRS)</measure>
    <time_frame>Change from baseline to 4 months</time_frame>
    <description>The Framingham Risk Score is calculated by a published algorithm that predicts a patients risk of having a coronary heart disease event in the next 10 years. The measures that are considering in predicting this risk are: age, blood pressure, cholesterol (both total cholesterol and high-density lipoprotein cholesterol), smoking status, and use of medication to treat hypertension. This risk score can be estimated using an online calculator (http://hp2010.nhlbihin.net/atpiii/calculator.asp)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Blood Pressure</measure>
    <time_frame>change from baseline to 4 months</time_frame>
    <description>Blood pressure was assessed by standard clinical methods (i.e., the same way it is measured during a routine clinic visit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Blood Lipids</measure>
    <time_frame>change from baseline to 4 months</time_frame>
    <description>Blood lipids include routine cholesterol measurements that are monitored in clinical practice. They are measured in blood after a blood draw is performed. The specific measurements include: a) total cholesterol, b) low-density lipoprotein cholesterol, c) high-density lipoprotein cholesterol, and d) triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Small Artery Elasticity</measure>
    <time_frame>change from baseline to 4 months</time_frame>
    <description>Small artery elasticity is a measure of vascular function, estimated through analysis of the blood pressure waveform. A sensor is placed on wrist over the radial pulse. The blood pressure waveform of the pulse is recorded and analyzed the elasticity, or compliance, of the small (and large) vasculature. Impaired artery elasticity, or increased stiffness, is an early sign of vascular disease that predicts risk for future cardiovascular events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes hsCRP (C-reactive Protein)</measure>
    <time_frame>change from baseline to 4 months</time_frame>
    <description>This biomarker represents systemic inflammation within in the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes IL-6 (Interleukin-6)</measure>
    <time_frame>change from baseline to 4 months</time_frame>
    <description>This biomarker represents systemic inflammation within in the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes TNFa (Tumor Necrosis Factor Alpha)</measure>
    <time_frame>change from baseline to 4 months</time_frame>
    <description>This biomarker represents systemic inflammation within in the body.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>HIV Infection</condition>
  <condition>Cardiovascular Disease Risk</condition>
  <arm_group>
    <arm_group_label>Lisinopril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lisinopril 10mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lisinopril Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill (matched to lisinopril) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pravastatin 20mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill (matched to pravastatin) once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>Participants randomized to take pravastatin (active) or matching placebo pill once daily</description>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_label>Pravastatin placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>Participants randomized to take lisinopril (active) or matching placebo pill once daily</description>
    <arm_group_label>Lisinopril</arm_group_label>
    <arm_group_label>Lisinopril Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV Infection with viral load 'undetectable' while taking antiretroviral therapy

          -  Age ≥40

          -  Framingham risk score (FRS) ≥5%, or ≥3% with ≥5 years of exposure to antiretroviral
             therapy

        Exclusion Criteria:

          -  Known cardiovascular disease or Framingham risk score (FRS) ≥20%

          -  Blood pressure ≥140/90

          -  LDL cholesterol ≥160 (with FRS &lt;10%), or ≥130 (with FRS 10-20%)

          -  Currently taking, or has a medication contraindication to take, a 'statin', an ACE
             inhibitor, or an angiotensin receptor blocker medication

          -  Cirrhosis or plasma ALT/AST levels &gt;2x upper limit of normal

          -  Chronic kidney disease and a creatinine &gt;2.0mg/dL

          -  Triglycerides &gt;500mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Baker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hennepin Faculty Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>September 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2009</study_first_posted>
  <results_first_submitted>January 16, 2012</results_first_submitted>
  <results_first_submitted_qc>March 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 18, 2012</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lisinopril/P-placebo</title>
          <description>Lisinopril 10mg and placebo (matched to pravastatin) once daily</description>
        </group>
        <group group_id="P2">
          <title>L-placebo/Pravastatin</title>
          <description>Placebo pill (matched to lisinopril) and Pravastatin 20mg once daily</description>
        </group>
        <group group_id="P3">
          <title>Lisinopril/Pravastatin</title>
          <description>Lisinopril 10mg and Pravastatin 20mg once daily</description>
        </group>
        <group group_id="P4">
          <title>L-placebo/P-placebo</title>
          <description>Placebo pill (matched to pravastatin) and placebo pill (matched to lisinopril) once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lisinopril/P-placebo</title>
          <description>Lisinopril 10mg and placebo (matched to pravastatin) once daily</description>
        </group>
        <group group_id="B2">
          <title>L-placebo/Pravastatin</title>
          <description>Placebo pill (matched to lisinopril) and Pravastatin 20mg once daily</description>
        </group>
        <group group_id="B3">
          <title>Lisinopril/Pravastatin</title>
          <description>Lisinopril 10mg and Pravastatin 20mg once daily</description>
        </group>
        <group group_id="B4">
          <title>L-placebo/P-placebo</title>
          <description>Placebo pill (matched to pravastatin) and placebo pill (matched to lisinopril) once daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="8"/>
                    <measurement group_id="B2" value="47" spread="12"/>
                    <measurement group_id="B3" value="48" spread="4"/>
                    <measurement group_id="B4" value="45" spread="7"/>
                    <measurement group_id="B5" value="48" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Stated (by Self-report) That They Had Side Effects</title>
        <description>Participants were asked at each visit if they had any side effects to study medication. They provided a yes or no answer, and if yes they specified what the side effect was.</description>
        <time_frame>4 months</time_frame>
        <population>Number of participants who stated (by self-report) that they had side effects</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril/P-placebo</title>
            <description>Lisinopril 10mg and placebo (matched to pravastatin) once daily</description>
          </group>
          <group group_id="O2">
            <title>L-placebo/Pravastatin</title>
            <description>Placebo pill (matched to lisinopril) and Pravastatin 20mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Lisinopril/Pravastatin</title>
            <description>Lisinopril 10mg and Pravastatin 20mg once daily</description>
          </group>
          <group group_id="O4">
            <title>L-placebo/P-placebo</title>
            <description>Placebo pill (matched to pravastatin) and placebo pill (matched to lisinopril) once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Stated (by Self-report) That They Had Side Effects</title>
          <description>Participants were asked at each visit if they had any side effects to study medication. They provided a yes or no answer, and if yes they specified what the side effect was.</description>
          <population>Number of participants who stated (by self-report) that they had side effects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Took &gt;90% of Their Doses (by Pill Count)</title>
        <description>The number of pills missing from study medication bottles was counted by study nurses at the completion of the study. The proportion of pills taken divided by the number of days the participant was enrolled in the study was calculated, and multiplied by 100, to generate the '% of doses taken'</description>
        <time_frame>4 months</time_frame>
        <population>Number of participants who took &gt;90% of their doses (by pill count)were studied. All participants who returned unused medications at end of the study were included for these analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril/P-placebo</title>
            <description>Lisinopril 10mg and placebo (matched to pravastatin) once daily</description>
          </group>
          <group group_id="O2">
            <title>L-placebo/Pravastatin</title>
            <description>Placebo pill (matched to lisinopril) and Pravastatin 20mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Lisinopril/Pravastatin</title>
            <description>Lisinopril 10mg and Pravastatin 20mg once daily</description>
          </group>
          <group group_id="O4">
            <title>L-placebo/P-placebo</title>
            <description>Placebo pill (matched to pravastatin) and placebo pill (matched to lisinopril) once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Took &gt;90% of Their Doses (by Pill Count)</title>
          <description>The number of pills missing from study medication bottles was counted by study nurses at the completion of the study. The proportion of pills taken divided by the number of days the participant was enrolled in the study was calculated, and multiplied by 100, to generate the '% of doses taken'</description>
          <population>Number of participants who took &gt;90% of their doses (by pill count)were studied. All participants who returned unused medications at end of the study were included for these analyses</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Month 4 in the Framingham Risk Score (FRS)</title>
        <description>The Framingham Risk Score is calculated by a published algorithm that predicts a patients risk of having a coronary heart disease event in the next 10 years. The measures that are considering in predicting this risk are: age, blood pressure, cholesterol (both total cholesterol and high-density lipoprotein cholesterol), smoking status, and use of medication to treat hypertension. This risk score can be estimated using an online calculator (http://hp2010.nhlbihin.net/atpiii/calculator.asp)</description>
        <time_frame>Change from baseline to 4 months</time_frame>
        <population>All participants had Framingham risk score (FRS) estimated at baseline and month 4. The change from baseline to month 4 was calculated as the outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril/P-placebo</title>
            <description>Lisinopril 10mg and placebo (matched to pravastatin) once daily</description>
          </group>
          <group group_id="O2">
            <title>L-placebo/Pravastatin</title>
            <description>Placebo pill (matched to lisinopril) and Pravastatin 20mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Lisinopril/Pravastatin</title>
            <description>Lisinopril 10mg and Pravastatin 20mg once daily</description>
          </group>
          <group group_id="O4">
            <title>L-placebo/P-placebo</title>
            <description>Placebo pill (matched to pravastatin) and placebo pill (matched to lisinopril) once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 4 in the Framingham Risk Score (FRS)</title>
          <description>The Framingham Risk Score is calculated by a published algorithm that predicts a patients risk of having a coronary heart disease event in the next 10 years. The measures that are considering in predicting this risk are: age, blood pressure, cholesterol (both total cholesterol and high-density lipoprotein cholesterol), smoking status, and use of medication to treat hypertension. This risk score can be estimated using an online calculator (http://hp2010.nhlbihin.net/atpiii/calculator.asp)</description>
          <population>All participants had Framingham risk score (FRS) estimated at baseline and month 4. The change from baseline to month 4 was calculated as the outcome.</population>
          <units>Percent probability of CHD event in 10yr</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" lower_limit="-2.3" upper_limit="1.1"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-2.6" upper_limit="0.4"/>
                    <measurement group_id="O3" value="-1.5" lower_limit="-2.1" upper_limit="0.5"/>
                    <measurement group_id="O4" value="-0.3" lower_limit="-0.7" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Blood Pressure</title>
        <description>Blood pressure was assessed by standard clinical methods (i.e., the same way it is measured during a routine clinic visit)</description>
        <time_frame>change from baseline to 4 months</time_frame>
        <population>n=17 Lisinopril vs. n=17 L-placebo The outcome is analyzed as the 'main effect' for lisinopril versus placebo, as standard for factorial study designs. Since lisinopril, but not pravastatin, influences blood pressure, the analysis defines Lisinopril and L-placebo groups by pooling across pravastatin groups (i.e., P-placebo + Pravastatin groups).</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril/L-placebo Treatment Effect</title>
            <description>Lisinopril vs. Lisinopril-placebo (regardless of Pravastatin status)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Blood Pressure</title>
          <description>Blood pressure was assessed by standard clinical methods (i.e., the same way it is measured during a routine clinic visit)</description>
          <population>n=17 Lisinopril vs. n=17 L-placebo The outcome is analyzed as the 'main effect' for lisinopril versus placebo, as standard for factorial study designs. Since lisinopril, but not pravastatin, influences blood pressure, the analysis defines Lisinopril and L-placebo groups by pooling across pravastatin groups (i.e., P-placebo + Pravastatin groups).</population>
          <units>(mmHG)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic BP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" lower_limit="-9.4" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" lower_limit="-7.3" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Blood Lipids</title>
        <description>Blood lipids include routine cholesterol measurements that are monitored in clinical practice. They are measured in blood after a blood draw is performed. The specific measurements include: a) total cholesterol, b) low-density lipoprotein cholesterol, c) high-density lipoprotein cholesterol, and d) triglycerides</description>
        <time_frame>change from baseline to 4 months</time_frame>
        <population>n = 18 Pravastatin vs. n = 16 P-placebo The outcome is analyzed as the 'main effect' for pravastatin versus placebo, as standard for factorial study designs. Since pravastatin, but not lisinopril, influences cholesterol, the analysis defines Pravastatin and P-placebo groups by pooling across lisinopril groups (i.e., L-placebo + Lisinopril group).</population>
        <group_list>
          <group group_id="O1">
            <title>Pravastatin/P-placebo Treatment Effect</title>
            <description>Pravastatin vs. Pravastatin-placebo (regardless of Lisinopril status)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Blood Lipids</title>
          <description>Blood lipids include routine cholesterol measurements that are monitored in clinical practice. They are measured in blood after a blood draw is performed. The specific measurements include: a) total cholesterol, b) low-density lipoprotein cholesterol, c) high-density lipoprotein cholesterol, and d) triglycerides</description>
          <population>n = 18 Pravastatin vs. n = 16 P-placebo The outcome is analyzed as the 'main effect' for pravastatin versus placebo, as standard for factorial study designs. Since pravastatin, but not lisinopril, influences cholesterol, the analysis defines Pravastatin and P-placebo groups by pooling across lisinopril groups (i.e., L-placebo + Lisinopril group).</population>
          <units>(mg/dL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" lower_limit="-18.74" upper_limit="15.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" lower_limit="-13.22" upper_limit="11.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="-8.42" upper_limit="10.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Small Artery Elasticity</title>
        <description>Small artery elasticity is a measure of vascular function, estimated through analysis of the blood pressure waveform. A sensor is placed on wrist over the radial pulse. The blood pressure waveform of the pulse is recorded and analyzed the elasticity, or compliance, of the small (and large) vasculature. Impaired artery elasticity, or increased stiffness, is an early sign of vascular disease that predicts risk for future cardiovascular events.</description>
        <time_frame>change from baseline to 4 months</time_frame>
        <population>Analysis presents the baseline-to-month4 difference between Lisinopril versus L-placebo groups; n=17 Lisinopril vs. n=17 L-placebo Our hypothesis for this secondary outcome was the 'main effect' for Lisinopril versus placebo would reduce inflammation. There was no interaction, so analyses define Lisinopril and L-placebo groups as for outcome #4</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril/L-placebo Treatment Effect</title>
            <description>Lisinopril vs. Lisinopril-placebo (regardless of Pravastatin status)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Small Artery Elasticity</title>
          <description>Small artery elasticity is a measure of vascular function, estimated through analysis of the blood pressure waveform. A sensor is placed on wrist over the radial pulse. The blood pressure waveform of the pulse is recorded and analyzed the elasticity, or compliance, of the small (and large) vasculature. Impaired artery elasticity, or increased stiffness, is an early sign of vascular disease that predicts risk for future cardiovascular events.</description>
          <population>Analysis presents the baseline-to-month4 difference between Lisinopril versus L-placebo groups; n=17 Lisinopril vs. n=17 L-placebo Our hypothesis for this secondary outcome was the 'main effect' for Lisinopril versus placebo would reduce inflammation. There was no interaction, so analyses define Lisinopril and L-placebo groups as for outcome #4</population>
          <units>mL/mmHgx100</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes hsCRP (C-reactive Protein)</title>
        <description>This biomarker represents systemic inflammation within in the body.</description>
        <time_frame>change from baseline to 4 months</time_frame>
        <population>Analysis presents the baseline-to-month4 difference between Lisinopril versus L-placebo groups; n=17 Lisinopril vs. n=17 L-placebo Our hypothesis for this secondary outcome was the 'main effect' for Lisinopril versus placebo would reduce inflammation. There was no interaction, so analyses define Lisinopril and L-placebo groups as for outcome #4</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril/L-placebo Treatment Effect</title>
            <description>Lisinopril vs. Lisinopril-placebo (regardless of Pravastatin status)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes hsCRP (C-reactive Protein)</title>
          <description>This biomarker represents systemic inflammation within in the body.</description>
          <population>Analysis presents the baseline-to-month4 difference between Lisinopril versus L-placebo groups; n=17 Lisinopril vs. n=17 L-placebo Our hypothesis for this secondary outcome was the 'main effect' for Lisinopril versus placebo would reduce inflammation. There was no interaction, so analyses define Lisinopril and L-placebo groups as for outcome #4</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes IL-6 (Interleukin-6)</title>
        <description>This biomarker represents systemic inflammation within in the body.</description>
        <time_frame>change from baseline to 4 months</time_frame>
        <population>Analysis presents the baseline-to-month4 difference between Lisinopril versus L-placebo groups; n=17 Lisinopril vs. n=17 L-placebo Our hypothesis for this secondary outcome was the 'main effect' for Lisinopril versus placebo would reduce inflammation. There was no interaction, so analyses define Lisinopril and L-placebo groups as for outcome #4</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril/L-placebo Treatment Effect</title>
            <description>Lisinopril vs. Lisinopril-placebo (regardless of Pravastatin status)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes IL-6 (Interleukin-6)</title>
          <description>This biomarker represents systemic inflammation within in the body.</description>
          <population>Analysis presents the baseline-to-month4 difference between Lisinopril versus L-placebo groups; n=17 Lisinopril vs. n=17 L-placebo Our hypothesis for this secondary outcome was the 'main effect' for Lisinopril versus placebo would reduce inflammation. There was no interaction, so analyses define Lisinopril and L-placebo groups as for outcome #4</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes TNFa (Tumor Necrosis Factor Alpha)</title>
        <description>This biomarker represents systemic inflammation within in the body.</description>
        <time_frame>change from baseline to 4 months</time_frame>
        <population>Analysis presents the baseline-to-month4 difference between Lisinopril versus L-placebo groups; n=17 Lisinopril vs. n=17 L-placebo Our hypothesis for this secondary outcome was the 'main effect' for Lisinopril versus placebo would reduce inflammation. There was no interaction, so analyses define Lisinopril and L-placebo groups as for outcome #4</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril/L-placebo Treatment Effect</title>
            <description>Lisinopril vs. Lisinopril-placebo (regardless of Pravastatin status)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes TNFa (Tumor Necrosis Factor Alpha)</title>
          <description>This biomarker represents systemic inflammation within in the body.</description>
          <population>Analysis presents the baseline-to-month4 difference between Lisinopril versus L-placebo groups; n=17 Lisinopril vs. n=17 L-placebo Our hypothesis for this secondary outcome was the 'main effect' for Lisinopril versus placebo would reduce inflammation. There was no interaction, so analyses define Lisinopril and L-placebo groups as for outcome #4</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lisinopril/P-placebo</title>
          <description>Lisinopril 10mg and placebo (matched to pravastatin) once daily</description>
        </group>
        <group group_id="E2">
          <title>L-placebo/Pravastatin</title>
          <description>Placebo pill (matched to lisinopril) and Pravastatin 20mg once daily</description>
        </group>
        <group group_id="E3">
          <title>Lisinopril/Pravastatin</title>
          <description>Lisinopril 10mg and Pravastatin 20mg once daily</description>
        </group>
        <group group_id="E4">
          <title>L-placebo/P-placebo</title>
          <description>Placebo pill (matched to pravastatin) and placebo pill (matched to lisinopril) once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was small with limited power to detect differences.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jason Baker</name_or_title>
      <organization>Minneapolis Medical Foundation</organization>
      <phone>612-873-2705</phone>
      <email>baker459@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

